

AMENDMENTS

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims

Claims 1-5 (cancelled)

*Sub* *1* *human*
Claim *6* (currently amended): *polypeptide* An isolated ~~compound~~ comprising a contiguous sequence of amino acids within the sequence representing residues 149-~~197~~*177* of the G protein of respiratory syncytial virus (RSV), wherein ~~more than one of~~ *human* cysteines 173; and 176, 182 and 186 is are absent or blocked, wherein said ~~compound~~ *polypeptide* is not glycosylated, and wherein said ~~compound~~ *polypeptide* has the ability to inhibit infectivity of RSV.

Claims 7-8 (cancelled)

*G contd.* *2*
Claim *9* (previously amended): *The polypeptide* A ~~compound~~ according to claim *6*, wherein one or more amino acids is replaced by its corresponding D-amino acid.

Sub *1*
Claim 10 (cancelled)

*3*
Claim *11* (previously amended): *The polypeptide* A ~~compound~~ according to claim *6*, wherein the compound is labelled with a detectable marker.

*4*
Claim *12* (previously amended): *The polypeptide* A ~~compound~~ according to claim *11*, wherein the detectable marker is a radioactive label.

*5*
Claim *13* (previously amended): *The polypeptide* A ~~compound~~ according to claim *11*, wherein the detectable marker is a fluorescent, chemiluminescent or enzymic marker.

Claims 14-15 (cancelled)

Claim 16 (withdrawn): An antibody directed against a compound selected from the group consisting of the compounds of Claims 1 to 10.

Claim 17 (withdrawn): An antibody according to Claim 16 which is a protective antibody.

Claim 18 (withdrawn): A composition comprising antibody selected from the group of the antibodies of Claim 16 and Claim 17.

Claims 19-20 (cancelled)

Claim 21 (withdrawn): A composition according to any one of Claim 16 in which the virus is human RSV.

61
Claim 22 (cancelled)

Claim 23 (withdrawn): A method of diagnosis of *Pneumovirus* infection, comprising exposing a biological fluid or sample from a mammal suspected of being infected with said virus to a compound selected from the group consisting of the compounds of Claims 1 to 10, and measuring the interaction between the compound and said fluid or sample.

Claim 24 (cancelled)

Claim 25 (withdrawn): A method of identification of a cell surface receptor for respiratory syncytial virus G protein, comprising the step of detection of binding of a compound selected from the group consisting of the compounds of Claims 11 to 13 to a cell surface protein.

Claim 26 (cancelled)

Claim 27 (withdrawn): A method according to Claim 25, in which the cell is susceptible to infection by respiratory syncytial virus.

Claim 28 (withdrawn): A method according to Claim 25, in which the cell is a HEp-2 cell.

Claim 29 (withdrawn): A method according to Claim 25, in which the method comprises the step of photoaffinity labelling of the receptor with a benzoylbenzyl derivative of the compound.

Claim 30 (withdrawn): A method according to Claim 25, in which the method comprises the step of labelling of the receptor with a fluorescent derivative of the compound.

6 Claim 31 (withdrawn): A method according to Claim 25, in which the method comprises the steps of binding a biotinylated derivative of the compound to a receptor, and binding of avidin to the derivative.

Claim 32 (withdrawn): A method according to Claim 25, in which the method comprises the step of using an antibody according to Claim 16 to detect the binding of the compound.

Claim 33 (withdrawn): A method according to Claim 25, in which the compound is multiply derivatised, thereby to achieve combined cross-linking, detection and identification of a receptor.

H
Sub
H
The polypeptide
6
Claim 34 (previously amended): A compound according to claim 6, wherein the contiguous sequence represents residues 149 to 177 of the G protein of RSV. human

7
H
the polypeptide
Claim 35 (previously amended): A diagnostic composition comprising a compound according to claim 6.

Claim 36 (cancelled)

Claim 37 (previously added): A diagnostic composition according to claim 36, wherein one or more amino acids is replaced by its corresponding D-amino acid.

Claim 38 (cancelled)

Claim 39 (previously amended): A composition comprising ~~a compound~~ ^{the polypeptide} according to claim 6, together with a pharmaceutically acceptable carrier.

Claim 40 (cancelled)

Claim 41 (previously amended): A composition comprising ~~a compound~~ ^{the polypeptide} according to claim 6, wherein one or more amino acids is replaced by its corresponding D-amino acid.

Claim 42 (cancelled)

Claim 43 (previously added): ~~A compound~~ ^{The polypeptide} according to claim 6, comprising the amino acid sequence KQRQNKPPSKPNNDHFHFEVFNFPVCSICG (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl.

Claim 44 (previously added): ~~A compound~~ ^{The polypeptide} according to claim 6, consisting of acetyl-KQRQNKPPSKPNNDHFHFEVFNFPVCSICGamide (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl.

Claim 45 (previously added): A method of inhibiting the cytopathic effect of RSV, comprising contacting an RSV susceptible cell with the ~~compound~~ ^{human polypeptide} of claim 6.

Claim 46 (previously added): A method according to claim 45, wherein the contiguous sequence of amino acids represents residues 149 to 177 of the G protein of RSV. ^{human}

Claim 48 (previously added): A method according to claim 45, wherein the compound is acetyl-KQRQNKPPSKPNNDFHFVFNFVPCSI¹CGAmide (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl.

cond. Claim ~~30~~ (currently amended): A ^{human} compound comprising a contiguous sequence of amino acids within the sequence representing residues 149-197 ^{human} ~~177~~ of the G protein of respiratory syncytial virus (RSV), wherein ~~neither~~ ^{neither} of cysteines 173; ^{polypeptide} ~~or~~ 176, 182 and 186 is functional to form a disulfide bridge, wherein said ^{human} ~~compound~~ is not glycosylated, and wherein said ^{polypeptide} ~~compound~~ has the ability to inhibit infectivity of RSV.